Stay updated on TIL and Anti-PD1 in Metastatic Melanoma Clinical Trial
Sign up to get notified when there's something new on the TIL and Anti-PD1 in Metastatic Melanoma Clinical Trial page.
![Latest website image capture](/pages/_next/image?url=https%3A%2F%2Fs3.us-west-2.amazonaws.com%2Fvp-files-ore%2Fresources%2F12months%2FLo25yvMVL60rCxB2IXpIxevfO9E.uncropped.jpg&w=3840&q=75)
Latest updates to the TIL and Anti-PD1 in Metastatic Melanoma Clinical Trial page
- CheckyesterdayNo Change Detected
- Check2 days agoNo Change Detected
- Check3 days agoNo Change Detected
- Check4 days agoNo Change Detected
- Check5 days agoChange DetectedThe website has been updated to Revision v2.9.7 from v2.9.6.SummaryDifference0.1%
- Check19 days agoChange DetectedThe value of Revision has been updated from v2.9.5 to v2.9.6, indicating a recent change in the webpage content.SummaryDifference0.1%
- Check24 days agoChange DetectedThe value of Revision has been updated from v2.9.3 to v2.9.5, indicating a recent change in the version of the content on the webpage.SummaryDifference0.1%
- Check25 days agoChange DetectedThe value of Revision has been updated from v2.9.1 to v2.9.3, indicating a recent revision in the content of the web page.SummaryDifference0.1%
- Check26 days agoChange DetectedThe value 'Show more Show more Revision: v2.9.0' has been updated to 'Show less MedlinePlus Genetics related topics: Melanoma MedlinePlus related topics: Melanoma Genetic and Rare Diseases Information Center resources: Neuroendocrine Tumor Neuroepithelioma Drug Information available for: Interferon Nivolumab FDA Drug and Device Resources'. This change reflects an update in the information provided on the webpage.SummaryDifference65%
- Check30 days agoChange DetectedThe recent change to revision v2.9.0 in the webpage represents an update to the study protocol for the ACTME trial, focusing on adoptive TIL therapy with low-dose IFN-alpha plus anti-PD1 in metastatic melanoma. The change includes details on the phase I/II study protocol, safety, and efficacy assessment for patients with metastatic melanoma refractory to standard care treatments.SummaryDifference9%
Stay in the know with updates to TIL and Anti-PD1 in Metastatic Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the TIL and Anti-PD1 in Metastatic Melanoma Clinical Trial page.